Of inquiry directing the President to provide certain documents in the President's possession to the House of Representatives relating to communications by or among any of the Department of Health and Human Services, the Office of National Drug Control Policy, the White House, the Drug Enforcement Administration, and the Department of Justice related to the executive branch's recommendations for a long-term, consensus approach to reduce the supply and availability of illicitly manufactured fentanyl-related substances in the United States.

Cost and committee reports

Official records Congress.gov attaches to H.Res. 1274.

• Committee reportCongress.gov lists 1 committee report for this bill: H. Rept. 117-527 ↗. The Congress.gov committee record lists a “Reported By” entry for the Energy and Commerce Committee on September 29, 2022.
  Source: Congress.gov, reported September 29, 2022 ↗

  Evidence

  Field in the Congress.gov record

  committeeReports

  Report API records

  https://api.congress.gov/v3/committee-report/117/HRPT/527

  Congress.gov bill record

  H.Res. 1274, 117th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/117/hres/1274

  Record last updated by Congress.gov

  April 7, 2025

  PORKER copy retrieved

  September 16, 2026

  Stored copy, SHA-256 of the file

  d1d8dafea7933e7139be6a3238f3081994f0107d49ac4322db1a01a88616237c

  A committee report is the committee’s own explanation of the bill. PORKER lists it and links to it; reading it is up to you.

Congress.gov’s record for this bill does not list a CBO cost estimate (as of April 7, 2025). Not every bill gets one.

From the Congress.gov bill record for H.Res. 1274, last updated April 7, 2025. PORKER’s copy was retrieved September 16, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.